Ilya Pharma appoints Oskar Lund as CFO

Uppsala, August 17, 2021: Ilya Pharma, a clinical stage cell & gene therapy company today announced that Oskar Lund has been appointed Chief Financial Officer. Lund joins at a pivotal stage in the Company's development as it eyes a potential IPO following recent positive results from the first in human (FIH) trial of its lead candidate ILP100 for treating difficult and chronic wounds.

Lund comes to Ilya from Disruptive Materials, another Uppsala-based life sciences startup, having engineered the strategic split of the company into two groups along with a successful c-round funding of the newly spun-out pharma business. This is backed by a strong track record of successful fund raising combined with in-depth financial management and strategic business development experience in the private, corporate and public sectors, including GE, BNP Paribas and JP Morgan.

"I am delighted to join Ilya Pharma at this exciting stage in the company's development. The underlying technology offers multiple opportunities for accelerated and sustained growth. I look forward to leveraging both my extensive Nordic and US networks and recent experience with Disruptive Materials in securing the capital and diverse shareholder base with an institutional focus to achieve this," comments Lund.

"Oskar is a key addition to the team as we enter a new phase of company development following the recently released FIH data,"says Evelina Vågesjö, Ilya Pharma's CEO. "I look forward to working with him on our ambitious strategy and major upcoming financing rounds including a possible IPO."

Notes to editors. 

Ilya Pharma is a clinical stage biopharma, developing novel drug candidates from its propriety technology platform to clinical proof of concept in relevant patient groups with identified unmet medical needs. ILP100 represents both a novel drug delivery technology and a novel investigational new product (IMP) and is classified as an advanced therapy medicinal product by the EMA and as a low-risk candidate under the gene therapy umbrella by the FDA.


Evelina Vågesjö, CEO

Tel: +46 (0) 70 636 64 94 


To read more People News articles, click here.